Bristol Myers Squibb (CELG-RI) Current Taxes (2009 - 2019)
Bristol Myers Squibb (CELG-RI) reported Current Taxes of $525.0 million for Q1 2019, up 77.36% year-over-year from $296.0 million in Q1 2018, and up 31.91% quarter-over-quarter from $398.0 million in Q4 2018.
Bristol Myers Squibb (CELG-RI) Current Taxes (2009 - 2019) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 11 years of Current Taxes data on file, last reported at $525.0 million in Q1 2019.
- Current Taxes for Q1 2019 came in at $525.0 million, up 77.36% year-over-year; the trailing twelve-month figure through Mar 2019 was $525.0 million (up 77.36% YoY), and the FY2018 annual result was $398.0 million, up 72.29% from the prior year.
- Current Taxes rose to $525.0 million in Q1 2019 per CELG-RI's latest filing, from $398.0 million in the prior quarter.
- Over five years, Current Taxes peaked at $572.0 million in Q4 2015 and troughed at $98.0 million in Q2 2015.
- A 5-year average of $295.9 million and a median of $291.0 million in 2017 frame the typical range for Current Taxes.
- The sharpest annual moves came in 2015 and 2016: Current Taxes soared 118.32% in 2015, then slumped 73.43% in 2016.
- A 5-year view of Current Taxes shows it stood at $572.0 million in 2015, then tumbled by 73.43% to $152.0 million in 2016, then soared by 51.97% to $231.0 million in 2017, then jumped by 72.29% to $398.0 million in 2018, then surged by 31.91% to $525.0 million in 2019.
- Business Quant data shows CELG-RI's Current Taxes at $525.0 million in Q1 2019, $398.0 million in Q4 2018, and $355.0 million in Q3 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -748.24 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 1.09 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 3.95 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 3.13 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 525.00 Mn |
| Dec 31, 2018 | 398.00 Mn |
| Sep 30, 2018 | 355.00 Mn |
| Jun 30, 2018 | 373.00 Mn |
| Mar 31, 2018 | 296.00 Mn |
| Dec 31, 2017 | 231.00 Mn |
| Sep 30, 2017 | 213.00 Mn |
| Jun 30, 2017 | 291.00 Mn |
| Mar 31, 2017 | 180.00 Mn |
| Dec 31, 2016 | 152.00 Mn |
| Sep 30, 2016 | 312.00 Mn |
| Jun 30, 2016 | 164.00 Mn |
| Mar 31, 2016 | 472.00 Mn |
| Dec 31, 2015 | 572.00 Mn |
| Sep 30, 2015 | 179.00 Mn |
| Jun 30, 2015 | 98.00 Mn |
| Mar 31, 2015 | 220.00 Mn |
| Dec 31, 2014 | 262.00 Mn |
| Sep 30, 2014 | 312.00 Mn |
| Jun 30, 2014 | 204.00 Mn |